



3047 Orchard Parkway, San Jose  
CA 95134 USA  
Tel (US) +1 (650) 390 9000  
Tel (AU): 1-800-778-662  
Fax: +1 650 390 9007  
[www.airxpanders.com](http://www.airxpanders.com)

**22 May 2018**

## **AirXpanders - Results of 2018 Annual Meeting of Stockholders**

**San Jose, CA, United States** – AirXpanders Inc (ASX: AXP) a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® tissue expander, today held its Annual Meeting of Stockholders and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Notice of Annual Meeting and Proxy Statement dated 30 April 2018 were passed. A summary of the resolutions passed follows below:

- Mr Barry Cheskin has been duly elected to serve as a Class III director of the Company until the 2021 Annual Meeting of Stockholders;
- the additional 10% placement facility has been approved;
- the grants of options to the non-executive directors have been approved;
- the issue of securities under the AirXpanders, Inc. 2015 Equity Incentive Plan as an exception to ASX Listing Rule 7.1 has been approved; and
- the appointment by the Audit and Risk Committee of the Board of Directors of SingerLewak LLP as the independent registered public accounting firm of AirXpanders for its fiscal year ending 31 December 2018 has been approved.

The information required under Section 251AA of the Corporations Act is attached.

- ENDS -

<b>Company</b>	<b>Investor relations</b>
Scott Murcay Interim President & CEO Tel: +1 (408)-242-8574 Email: <a href="mailto:smurcay@airxpanders.com">smurcay@airxpanders.com</a>	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 / + 61 (0)401018828 Email: <a href="mailto:kwilliamson@we-buchan.com">kwilliamson@we-buchan.com</a>

### **About AirXpanders**

Founded in 2005, AirXpanders, Inc. ([www.airxpanders.com](http://www.airxpanders.com)) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The Company's AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publicly listed Company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA *de novo* marketing authorization in 2016, first CE mark in Europe in 2012 and is currently licensed for sale in Australia.

For more information, refer to the Company's website at [www.airxpanders.com](http://www.airxpanders.com).

**AIRXPANDERS, INC.**  
**2018 Annual General Meeting**  
**Tuesday, 22 May 2018**  
**Voting Results**

Resolution details		Instructions given to validly appointed proxies (as at proxy close)			Resolution Result
Resolution	Resolution Type	For	Against	Withheld	Carried / Not Carried
1 Re-election of Mr Barry Cheskin as a Class III Director of the Company	Ordinary	56,223,904 78.77%		15,155,761 21.23%	Carried
Resolution	Resolution Type	For	Against	Abstain	Carried / Not Carried
2 Approval of 10% Placement Facility	Special	70,919,066 99.36%	416,744 0.58%	43,617 0.06%	Carried
3A Grant of Options to Mr Barry Cheskin	Ordinary	40,377,378 56.56%	30,325,587 42.49%	676,462 0.95%	Carried
3B Grant of Options to Mr Dennis Condon	Ordinary	55,308,831 77.48%	15,394,134 21.57%	676,462 0.95%	Carried
3C Grant of Options to Ms Elizabeth Hammack	Ordinary	55,310,123 77.49%	15,392,842 21.56%	676,462 0.95%	Carried
3D Grant of Options to Mr Gregory Lichtwardt	Ordinary	55,310,123 77.49%	15,392,842 21.56%	676,462 0.95%	Carried
3E Grant of Options to Ms Zita Peach	Ordinary	55,330,252 77.52%	15,392,842 21.56%	656,333 0.95%	Carried
4 Approval of issue of securities under the AirXpanders. Inc. 2015 Equity Incentive Plan	Ordinary	56,002,360 78.46%	15,366,550 21.53%	10,517 0.01%	Carried
5 To ratify the appointment of SingerLewak LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018	Ordinary	71,121,627 99.64%	43,989 0.06%	213,811 0.30%	Carried